GRD1
MCID: GRV008
MIFTS: 56

Graves Disease 1 (GRD1)

Categories: Endocrine diseases, Immune diseases, Rare diseases

Aliases & Classifications for Graves Disease 1

MalaCards integrated aliases for Graves Disease 1:

Name: Graves Disease 1 56
Thyrotoxicosis 56 12 43 15 17 71
Graves Disease, Susceptibility to, 1 56 13
Hyperthyroidism, Autoimmune 56
Grd1 56
Grd 56

Characteristics:

OMIM:

56
Inheritance:
autosomal recessive vs. dominant with relative sex limitation to females and reduced penetrance postulated, but more likely multifactorial


HPO:

31
graves disease 1:
Inheritance autosomal recessive inheritance


Classifications:



Summaries for Graves Disease 1

OMIM : 56 Graves disease is an autoimmune disorder in which antibodies to the thyrotropin receptor (TSHR; 603372) result in constitutive activation of the receptor and increased levels of thyroid hormone. Wilkin (1990) reviewed endocrine disorders of hormone excess and hormone deficiency resulting from receptor autoimmunity. (275000)

MalaCards based summary : Graves Disease 1, also known as thyrotoxicosis, is related to neonatal thyrotoxicosis and thyrotoxic periodic paralysis. An important gene associated with Graves Disease 1 is GRD1 (Graves Disease, Susceptiblity To, 1), and among its related pathways/superpathways are Aldosterone synthesis and secretion and Angiopoietin Like Protein 8 Regulatory Pathway. The drugs Methimazole and Diclofenac have been mentioned in the context of this disorder. Affiliated tissues include thyroid, heart and bone, and related phenotypes are muscle weakness and hyperhidrosis

Disease Ontology : 12 A thyroid gland disease that is characterized by excess thyroid hormone.

Related Diseases for Graves Disease 1

Diseases in the Graves' Disease family:

Graves Disease 1 Graves Disease 2

Diseases related to Graves Disease 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 594)
# Related Disease Score Top Affiliating Genes
1 neonatal thyrotoxicosis 33.7 TSHR TG SLC16A2 DIO3 DIO2
2 thyrotoxic periodic paralysis 33.2 TSHR KCNJ18 CACNA1S
3 subacute thyroiditis 32.6 TSHR TPO TG SHBG SERPINA7
4 thyrotoxic periodic paralysis 1 32.6 KCNJ18 CACNA1S
5 thyroid crisis 32.6 TSHR TPO THRB TG SERPINA7
6 hypokalemic periodic paralysis, type 1 32.3 SCN4A KCNJ18 INS CACNA1S
7 hashimoto thyroiditis 31.7 TSHR TPO TG DIO2
8 thyroid carcinoma 31.5 TSHR TPO TG
9 exophthalmos 31.4 TSHR TPO TG
10 multinodular goiter 31.2 TSHR TPO TG PTH
11 plummer's disease 31.1 TSHR TPO THRB TG SHBG PTH
12 periodic paralysis 31.1 SCN4A KCNJ18 CACNA1S
13 hyperthyroidism 31.0 TSHR TRH TPO THRB TG SLC16A2
14 nodular goiter 30.7 TSHR TPO TG SLC5A5
15 thyroiditis 30.7 TSHR TRH TPO THRB TG SERPINA7
16 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 30.7 TSHR TPO TG INS
17 hypoparathyroidism 30.7 TPO PTH INS
18 struma ovarii 30.6 TSHR TG
19 exophthalmic ophthalmoplegia 30.6 POMC KCNJ18
20 papillary carcinoma 30.6 TSHR TPO TG
21 thyroid cancer, nonmedullary, 2 30.6 TSHR THRB TG
22 endemic goiter 30.5 TSHR TPO TG SERPINA7 PTH
23 adenoma 30.4 TSHR TRH TG PTH POMC
24 differentiated thyroid carcinoma 30.4 TSHR TPO TG
25 follicular adenoma 30.4 TSHR TPO TG
26 acute thyroiditis 30.3 TPO TG SERPINA7 POMC
27 toxic diffuse goiter 30.3 TSHR TPO TG SERPINA7
28 postsurgical hypothyroidism 30.3 TRH TPO TG PTH
29 athyreosis 30.2 TSHR TG
30 myxedema 30.2 TSHR TPO TG SERPINA7 SEM1 POMC
31 thyroid hormone resistance, selective pituitary 30.2 TXNRD2 TRH THRB
32 primary hyperparathyroidism 30.2 PTH POMC INS
33 substernal goiter 30.2 TG PTH
34 hyperthyroxinemia 30.2 TSHR TRH TPO THRB TG SERPINA7
35 iodine hypothyroidism 30.2 TSHR TPO TG
36 pituitary apoplexy 30.2 TRH POMC INS
37 diabetes insipidus 30.1 TG POMC INS
38 thyroid gland anaplastic carcinoma 30.1 TSHR TPO TG SLC5A5
39 uvulitis 30.1 KCNJ18 INS
40 hypothyroidism, congenital, nongoitrous, 1 30.0 TSHR TG PTH
41 hypopituitarism 30.0 TRH SHBG POMC INS
42 hyperkalemic periodic paralysis 30.0 SCN4A KCNJ18 CACNA1S
43 acromegaly 29.9 TRH SHBG POMC INS
44 hypokalemia 29.9 SCN4A POMC KCNJ18 INS CACNA1S
45 endogenous depression 29.9 TRH POMC INS
46 sheehan syndrome 29.8 POMC INS
47 goiter 29.8 TXNRD2 TSHR TRH TPO THRB TG
48 andersen cardiodysrhythmic periodic paralysis 29.7 SCN4A KCNJ18 CACNA1S
49 paramyotonia congenita of von eulenburg 29.7 SCN4A KCNJ18 CACNA1S
50 hyperpituitarism 29.7 TRH POMC INS

Graphical network of the top 20 diseases related to Graves Disease 1:



Diseases related to Graves Disease 1

Symptoms & Phenotypes for Graves Disease 1

Human phenotypes related to Graves Disease 1:

31 (show all 15)
# Description HPO Frequency HPO Source Accession
1 muscle weakness 31 HP:0001324
2 hyperhidrosis 31 HP:0000975
3 abnormality of metabolism/homeostasis 31 HP:0001939
4 irritability 31 HP:0000737
5 weight loss 31 HP:0001824
6 hyperreflexia 31 HP:0001347
7 congestive heart failure 31 HP:0001635
8 proptosis 31 HP:0000520
9 goiter 31 HP:0000853
10 hyperactivity 31 HP:0000752
11 onycholysis 31 HP:0001806
12 polyphagia 31 HP:0002591
13 graves disease 31 HP:0100647
14 pretibial myxedema 31 HP:0200028
15 abnormality of abdomen morphology 31 HP:0001438

Symptoms via clinical synopsis from OMIM:

56
Muscle:
muscle weakness

Neuro:
hyperreflexia

Skin:
pretibial myxedema
increased sweating

Endocrine:
thyrotoxicosis

G I:
increased appetite
gi hypermotility

Lab:
high t4 and t3
high rai
low serum tsh

Misc:
irritability
weight loss
hyperactivity
nervousness
hyperpyrexia

Neck:
goiter

Eyes:
exophthalmos

Nails:
oncholysis

Cardiac:
high output congestive heart failure

Clinical features from OMIM:

275000

MGI Mouse Phenotypes related to Graves Disease 1:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.03 CACNA1S DIO2 DIO3 INS POMC PTH
2 endocrine/exocrine gland MP:0005379 10.02 DIO2 INS POMC PTH SLC5A5 TG
3 homeostasis/metabolism MP:0005376 10 CACNA1S DIO2 DIO3 INS POMC SCN4A
4 nervous system MP:0003631 9.7 CACNA1S INS POMC SERPINA7 SLC16A2 SLC5A5
5 skeleton MP:0005390 9.32 CACNA1S DIO2 INS PTH SLC5A5 TG

Drugs & Therapeutics for Graves Disease 1

Drugs for Graves Disease 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 107)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methimazole Approved Phase 4 60-56-0 1349907
2
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
3
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
4
Propranolol Approved, Investigational Phase 4 525-66-6 4946
5
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
6
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
7
Iodine Approved, Investigational Phase 4 7553-56-2 807
8 Antithyroid Agents Phase 4
9 Analgesics, Non-Narcotic Phase 4
10 Adrenergic beta-1 Receptor Antagonists Phase 4
11 Neurotransmitter Agents Phase 4
12 Antihypertensive Agents Phase 4
13 Adrenergic Agents Phase 4
14 Sympatholytics Phase 4
15 Adrenergic Antagonists Phase 4
16 Cyclooxygenase Inhibitors Phase 4
17 Anti-Arrhythmia Agents Phase 4
18 Analgesics Phase 4
19 Vasodilator Agents Phase 4
20 Adrenergic beta-Antagonists Phase 4
21 Anti-Inflammatory Agents Phase 4
22 Antirheumatic Agents Phase 4
23 Anti-Inflammatory Agents, Non-Steroidal Phase 4
24 Gastrointestinal Agents Phase 4
25 Antineoplastic Agents, Hormonal Phase 4
26 Antiemetics Phase 4
27 BB 1101 Phase 4
28 glucocorticoids Phase 4
29 Pharmaceutical Solutions Phase 4
30 Lugol's solution Phase 4
31 cadexomer iodine Phase 4
32
tannic acid Approved Phase 3 1401-55-4
33
Propylthiouracil Approved, Investigational Phase 3 51-52-5 657298
34
Carbimazole Approved, Investigational Phase 3 22232-54-8 31072
35
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
36 Antimetabolites Phase 3
37
Amiodarone Approved, Investigational Phase 2 1951-25-3 2157
38
Selenium Approved, Investigational, Vet_approved Phase 2 7782-49-2
39
Doxycycline Approved, Investigational, Vet_approved Phase 1, Phase 2 564-25-0 54671203
40
Oxytetracycline Approved, Investigational, Vet_approved Phase 1, Phase 2 79-57-2 54715139 5280972
41
Propofol Approved, Investigational, Vet_approved Phase 2 2078-54-8 4943
42
Ephedrine Approved Phase 2 299-42-3 9294
43
Phenylephrine Approved Phase 2 59-42-7 6041
44
Pseudoephedrine Approved Phase 2 90-82-4 7028
45
Oxymetazoline Approved, Investigational Phase 2 1491-59-4 4636
46
Guaifenesin Approved, Investigational, Vet_approved Phase 2 93-14-1 3516
47
3,5-diiodothyropropionic acid Investigational Phase 1, Phase 2 1158-10-7
48 Trace Elements Phase 2
49 Antioxidants Phase 2
50 Protective Agents Phase 2

Interventional clinical trials:

(show all 42)
# Name Status NCT ID Phase Drugs
1 Adjuvant Treatment of Graves´ Ophthalmopathy With NSAID (aGO Study) Completed NCT01458600 Phase 4 Diclofenac;Methimazole;L-thyroxin;Propranolol;Metoprolol
2 Prevention Relapse of Graves' Disease by Treatment With Intrathyroid Injection of Dexamethasone Completed NCT00917241 Phase 4 MMI combined with IID;MMI
3 Randomized Clinical Trial, Blinded for the Researcher and Multicenter, to Evaluate the Efficacy and Safety of Preoperative Preparation With Lugol Solution in Euthyroid Patients With Graves-Basedow Disease. Recruiting NCT03980132 Phase 4 Lugols Strong Iodine
4 Prospective Randomized Clinical Trial of Total Thyroidectomy (Tx) Versus Thionamides (Anti-Thyroid Drugs) in Patients With Moderate-to-Severe Graves' Ophthalmopathy - a 1-year Follow-up Unknown status NCT03066076 Phase 3 Antithyroid Drug
5 A Randomised Study of Two Anti-thyroid Drug Treatment Regimens in Young People Completed NCT01436994 Phase 3 carbimazole;propylthiouracil;thyroxine
6 The Effect of Subantimicrobial Dose Doxycycline in Mild Graves' Orbitopathy Unknown status NCT02203682 Phase 2 Doxycycline;placebo
7 Neuropsychologic and Immunological Evaluation in Treatment of Thyroid Diseases. Is Selenium Efficient? Completed NCT01247077 Phase 2
8 Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy: a Prospective, Uncontrolled Pilot Study Completed NCT01727973 Phase 1, Phase 2 Doxycycline
9 Oral Propranolol Versus Placebo for Early Stages of Retinopathy of Prematurity (ROP): A Pilot, Randomized and Prospective Study. Completed NCT01238471 Phase 1, Phase 2 propranolol;sucrose 5%
10 The Intra-Operative Application of Amiodarone Releasing Hydrogel to Prevent Postoperative Atrial Fibrillation in Patients Undergoing Lung Transplantation Completed NCT03221764 Phase 2 Amiodarone with CoSeal
11 Preoperative Ephedrine Attenuates the Hemodynamic Responses of Propofol During Valve Surgery: A Dose Dependent Study Completed NCT01006863 Phase 2 Ephedrine;Placebo;Phenylephrine
12 Tiratricol Treatment of Children With Monocarboxylate Transporter 8 Deficiency: Triac Trial II Not yet recruiting NCT02396459 Phase 2 Triac
13 A Randomized, Double-Blind Placebo-Controlled Study of 3,5-diiodothyropropionic Acid (DITPA) in Combination With Standard Therapy to Attain NCEP ATP III Goal for LDL Cholesterol in Hypercholesterolemic Patients Terminated NCT00311987 Phase 1, Phase 2 3,5-Diiodothyropropionic acid (DITPA) therapy
14 If Channel Blockade With Ivabradine in Patients With Diastolic Heart Failure Withdrawn NCT00757055 Phase 2 Ivabradine;Placebo
15 Effect of Denosumab in Reversing Periprosthetic Bone Loss Following Hip Replacement Unknown status NCT02444585 Phase 1 Denosumab
16 Application of Digital Infrared Thermal Imaging in Thyroid Disease and Associated Ophthalmopathy and Dermopathy Unknown status NCT01182584
17 Congestive Heart Failure: Causes of Sudden Worsening Unknown status NCT01081925
18 Hypothyroidism in Patients With Type 2 Diabetes With Early Diabetic Nephropathy Unknown status NCT03178253
19 Thyroid Dysfunction in Patients With Type 2 Diabetes With Early Diabetic Nephropathy. Unknown status NCT03154398
20 Phase 3b, Multicenter, Open-label, Single-Arm Expanded Access Protocol of TEPROTUMUMAB (HZN-001) Approved for marketing NCT04040894
21 Clinical Application of Continuous Monitoring Data for the Pulse Rate, Exercise, and Calorie Intake by Wearable Activity Trackers in the Patients With Thyrotoxicosis Completed NCT03009357
22 Differential Diagnosis Value of Peak Systolic Velocity of Thyroid Superior Artery Using Color Flow Doppler Sonography in Transient Thyrotoxicosis Caused by Thyroiditis and Graves Disease Completed NCT01227499
23 Efficacy of Thiamine Supplement for Improve Cardiovascular Function in Patients With Severe Hyperthyroidism Completed NCT02767245 Thiamine
24 POST-RADIOIODINE GRAVES' MANAGEMENT Completed NCT01885533
25 Genetic Analysis of Thai Patients With Thyrotoxic Periodic Paralysis Completed NCT00443833
26 Prevention of Iodinated Contrast Media Induced Hyperthyroidism in Patients With Euthyroid Goiter Completed NCT04304794 Prophylactic administration of antithyroid drugs before iodinated contrast media exposure
27 Hyperthyroid Follow-Up Study Completed NCT02989103
28 Low Doses of Cholestyramine in the Treatment of Hyperthyroidism Completed NCT00677469 Cholestyramine;Cholestyramine;Placebo powder
29 Cardiac Effects of Thyrotropin Over-Suppression With Levothyroxine in Young Women With Differentiated Thyroid Cancer Completed NCT02645786
30 The Use of Harmonic Scalpel Versus Knot Tying for Total Thyroidectomy: A Prospective Randomized Study Completed NCT01189955
31 Perioperative Perfusion Measurement - a Feasibility and Usability Study Completed NCT03671642
32 Early Versus Late DC-cardioversion of Persistent Atrial Fibrillation. Effect on Atrial Remodeling,Inflammatory and Neurohumoral Markers and Recurrence of Atrial Fibrillation. Completed NCT01593150 Pradaxa
33 Pilot Study for Treatment of Amiodarone-Induced Thyroiditis With Radiofrequency Ablation Recruiting NCT03720210
34 The Relationship of Vascular Cell Adhesion Molecule 1, C-reactive Protein, Brain-derived Neurotrophic Factor, Orexin and Depressive Symptoms in the Subjects With Thyroid Disease Recruiting NCT02886949
35 Bio-psycho-social Correlates of Psychological Distress in Patients With Graves' Disease in Euthyroid Status Recruiting NCT02620085
36 Personalized Treatment Planning for Radio-iodine Therapy of Thyroid Disease Recruiting NCT03517579
37 Identification and Regulation of Brown Adipose Tissue (BAT) in Humans. Implications for Energy Expenditure in Humans and in the Treatment of Obesity and Related Metabolic Diseases Active, not recruiting NCT02133040
38 Appréciation de la Prise en Charge de la Fibrillation Atriale Aux Urgences Active, not recruiting NCT03836339
39 Observational and Diagnostical Study on Transient Allostatic Responses of Thyroid Function After Cardiopulmonary Resuscitation Not yet recruiting NCT04392258
40 Does Serum BNP Predict Abnormal Placental Invasion During Pregnancy Not yet recruiting NCT04215484
41 Quantitative Fluorescent Guided Robotic Surgery for Cancer of the Gastroesophageal Junction Not yet recruiting NCT04107623
42 A Study Into the Effect of Seprafilm on Post Operative Adhesions After Open Total Thyroidectomy. Terminated NCT01865838

Search NIH Clinical Center for Graves Disease 1

Inferred drug relations via UMLS 71 / NDF-RT 50 :


levothyroxine
Levothyroxine Sodium
liothyronine
liothyronine sodium
Potassium Iodide
POTASSIUM IODIDE GRANULES
Thyroglobulin
THYROID (BEEF)
thyroid (USP)
THYROID PWDR

Cochrane evidence based reviews: thyrotoxicosis

Genetic Tests for Graves Disease 1

Anatomical Context for Graves Disease 1

MalaCards organs/tissues related to Graves Disease 1:

40
Thyroid, Heart, Bone, Testes, Liver, Pituitary, Cortex

Publications for Graves Disease 1

Articles related to Graves Disease 1:

(show top 50) (show all 7751)
# Title Authors PMID Year
1
The thyrotropin receptor autoantigen in Graves disease is the culprit as well as the victim. 61 56
12813025 2003
2
Thyroid-stimulating immunoglobulins and thyroid function tests in two siblings with neonatal thyrotoxicosis. 61 56
2874029 1986
3
Graves' disease associated with familial deficiency of thyroxine-binding globulin. 56 61
402376 1977
4
Humoral and genetic factors in thyrotoxic Graves disease and neonatal thyrotoxicosis. 56 61
946443 1976
5
The hereditary and familial aspects of toxic nodular goitre (secondary thyrotoxicosis). 61 56
14883303 1951
6
A genome-wide association study identifies two new risk loci for Graves' disease. 56
21841780 2011
7
Association of the thyroid stimulating hormone receptor gene (TSHR) with Graves' disease. 56
19244275 2009
8
Genomic polymorphism at the interferon-induced helicase (IFIH1) locus contributes to Graves' disease susceptibility. 56
17535987 2007
9
Association of the TSHR gene with Graves' disease: the first disease specific locus. 56
16106256 2005
10
Multiple SNPs in intron 7 of thyrotropin receptor are associated with Graves' disease. 56
15741259 2005
11
Regression mapping of association between the human leukocyte antigen region and Graves disease. 56
15558498 2005
12
Choanal atresia associated with prenatal methimazole exposure: three new patients. 56
15266622 2004
13
Intercellular adhesion molecule 1 gene polymorphisms in Graves' disease. 56
14557478 2003
14
Retinal microvascular abnormalities in patients treated with external radiation for graves ophthalmopathy. 56
12742842 2003
15
Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. 56
12724780 2003
16
Association study of autoimmune thyroid disease at 5q23-q33 in Japanese patients. 56
12768441 2003
17
Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in hyperthyroid patients. 56
12466365 2002
18
A polymorphism within the vitamin D-binding protein gene is associated with Graves' disease but not with Hashimoto's thyroiditis. 56
12050214 2002
19
Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study. 56
11502779 2001
20
Vitamin D receptor gene polymorphism is associated with Graves' disease in the Japanese population. 56
11134121 2000
21
The human leukocyte antigen HLA DRB3*020/DQA1*0501 haplotype is associated with Graves' disease in African Americans. 56
10770195 2000
22
HLA-DRB1*08, DRB1*03/DRB3*0101, and DRB3*0202 are susceptibility genes for Graves' disease in North American Caucasians, whereas DRB1*07 is protective. 56
10487684 1999
23
The cytotoxic T lymphocyte antigen-4 is a major Graves' disease locus. 56
10369864 1999
24
Linkage disequilibrium between the human leukocyte antigen class II region of the major histocompatibility complex and Graves' disease: replication using a population case control and family-based study. 56
9768636 1998
25
Linkage analysis of candidate genes in autoimmune thyroid disease. II. Selected gender-related genes and the X-chromosome. International Consortium for the Genetics of Autoimmune Thyroid Disease. 56
9745443 1998
26
Mapping of a major susceptibility locus for Graves' disease (GD-1) to chromosome 14q31. 56
9141566 1997
27
CTLA4 alanine-17 confers genetic susceptibility to Graves' disease and to type 1 diabetes mellitus. 56
8989248 1997
28
Induction of Graves-like disease in mice by immunization with fibroblasts transfected with the thyrotropin receptor and a class II molecule. 56
8855311 1996
29
Analysis of the thyrotropin receptor as a candidate gene in familial Graves' disease. 56
8855789 1996
30
Pathogenesis of Graves' ophthalmopathy. 56
8413459 1993
31
Receptor autoimmunity in endocrine disorders. 56
2170843 1990
32
Relative predispositional effects (RPEs) of marker alleles with disease: HLA-DR alleles and Graves disease. 56
2491013 1989
33
Two major genes, linked to HLA and Gm, control susceptibility to Graves' disease. 56
6894965 1981
34
A study of human leukocyte D locus related antigens in Graves' disease. 56
105012 1979
35
Genetics of Graves' disease. 56
4678502 1972
36
The hereditary and familial aspects of exophthalmic goitre and nodular goitre. 56
21011421 1945
37
Letter to the Editor: " Comparison Between Total Thyroidectomy and Medical Therapy for Amiodarone-Induced Thyrotoxicosis ". 61
32445572 2020
38
Response to the Letter to the Editor: "Comparison Between Total Thyroidectomy and Medical Therapy for Amiodarone-Induced Thyrotoxicosis". 61
32445571 2020
39
A contemporary analysis of goiters undergoing surgery in the United States. 61
31948703 2020
40
Management of fetal goiters: 6-year retrospective observational study in three prenatal diagnosis and treatment centers of the Pays De Loire Perinatal Network. 61
30513035 2020
41
A systematic review of the incidence of thyroid carcinoma in patients undergoing thyroidectomy for thyrotoxicosis. 61
32149464 2020
42
ENDOCRINOLOGY IN THE TIME OF COVID-19: Management of hyperthyroidism and hypothyroidism. 61
32438340 2020
43
The interplay between thyroid and liver: implications for clinical practice. 61
32166702 2020
44
Disease characteristics of MCT8 deficiency: an international, retrospective, multicentre cohort study. 61
32559475 2020
45
TSH suppressive therapy and bone. 61
32567550 2020
46
Thyroid Disease in Pregnancy: ACOG Practice Bulletin Summary, Number 223. 61
32443078 2020
47
Thyroid Disease in Pregnancy: ACOG Practice Bulletin, Number 223. 61
32443080 2020
48
Hypnosis and superficial cervical anesthesia for total thyroidectomy in a high-risk patient - A case report. 61
32535527 2020
49
Ecological momentary assessments (EMA) did not improve responsiveness of patient-reported outcomes on quality of life. 61
32525086 2020
50
The Influence of Thyroid Hormones on Brain Structure and Function in Humans. 61
32040963 2020

Variations for Graves Disease 1

Expression for Graves Disease 1

Search GEO for disease gene expression data for Graves Disease 1.

Pathways for Graves Disease 1

GO Terms for Graves Disease 1

Biological processes related to Graves Disease 1 according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 transmembrane transport GO:0055085 9.92 SLC5A5 SLC16A2 SEM1 SCN4A CACNA1S
2 cell-cell signaling GO:0007267 9.65 TSHR TRH PTH POMC INS
3 hormone-mediated signaling pathway GO:0009755 9.63 TSHR TRH THRB
4 positive regulation of glycogen biosynthetic process GO:0045725 9.51 PTH INS
5 retinal cone cell development GO:0046549 9.49 THRB DIO3
6 thyroid hormone transport GO:0070327 9.48 SLC16A2 SERPINA7
7 iodide transport GO:0015705 9.43 TG SLC5A5
8 retinal cone cell apoptotic process GO:0097474 9.4 THRB DIO3
9 negative regulation of eye photoreceptor cell development GO:0042480 9.37 THRB DIO3
10 thyroid hormone metabolic process GO:0042403 9.33 TG DIO3 DIO2
11 thyroid hormone catabolic process GO:0042404 9.32 DIO3 DIO2
12 hormone biosynthetic process GO:0042446 9.26 TPO TG DIO3 DIO2
13 thyroid hormone generation GO:0006590 9.1 TPO TG SLC5A5 SLC16A2 DIO3 DIO2

Molecular functions related to Graves Disease 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 thyroxine 5'-deiodinase activity GO:0004800 9.16 DIO3 DIO2
2 hormone activity GO:0005179 9.02 TRH TG PTH POMC INS
3 thyroxine 5-deiodinase activity GO:0033798 8.96 DIO3 DIO2

Sources for Graves Disease 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....